Holen Sie sich die Stockscreener-App
23.02
1.96%
-0.46
Handel nachbörslich:
19.37
-3.65
-15.86%
Schlusskurs vom Vortag:
$23.48
Offen:
$22.3
24-Stunden-Volumen:
40.36M
Relative Volume:
2.04
Marktkapitalisierung:
$5.24B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
33.36
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-15.02%
1M Leistung:
-35.08%
6M Leistung:
-54.98%
1J Leistung:
-43.12%
1-Tages-Spanne:
$21.12
$23.62
1-Wochen-Bereich:
$21.12
$27.77
52-Wochen-Spanne:
$21.12
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
23.02 | 5.35B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.89 | 56.23B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
127.42 | 55.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.98 | 48.36B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.69 | 40.01B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.36 | 20.62B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers pulls copycat weight-loss pill - Semafor
Hims & Hers Suddenly Pulls Its $49 Wegovy Copycat After FDA Threatens Action - inc.com
HIMS Discontinues Compounded Semaglutide Pill Amid Stakeholder D - GuruFocus
Hims & Hers (HIMS) Stock Crashes as Company Pulls Plug on Wegovy Copy - MEXC
A $49 Ozempic Alternative Just Launched. Novo Nordisk Says It’s ‘Illegal’ and Dangerous - inc.com
Hims & Hers is promoting a new product to the massive NFL audience: a blood test designed to detect more than 50 types of cancer before symptoms show up. But the test’s reliability is questionable. - Facebook
Hims & Hers Halts Compounded Semaglutide Pill Offering After FDA's Crackdown Warning - Benzinga
AI for investors - MLQ.ai
A $700 blood test promises to detect 50 different kinds of cancer. The results come with major caveats. - Business Insider
Hims & Hers (HIMS) Shares Sink 16% as FDA Crackdown Halts Wegovy Copycat Pill - TipRanks
Hims Withdraws GLP-1 Weight Loss Pill After FDA Warning and Lawsuit Threats - AOL.com
Telehealth company scraps plans to sell cheap GLP-1 diet pill after FDA vows crackdown - New York Post
Hims & Hers responds to FDA pressure, pulls knockoff Wegovy drug launch after regulatory threats - Fox Business
Hims & Hers halts sale of Wegovy copycat pill following FDA crackdown on weight-loss drugs - Mint
Hims cancels plans to sell compounded GLP-1 pill after FDA backlash - BioPharma Dive
Hims & Hers removes a knock-off weight loss drug days after introducing it - Business Insider
Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill - Ottumwa Courier
HIMS Halts Compounded Weight-Loss Pill Amid Regulatory Pressure - GuruFocus
Hims & Hers Halts Sales of Wegovy Drug Amid FDA Pressure - intellectia.ai
Hims to stop offering GLP-1 pill after FDA warned of crackdown - KSL.com
Hims & Hers scraps copycat Wegovy weight-loss pill after probe - Fortune
Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny - Barron's
Analysts Conflicted on These Healthcare Names: Encompass Health (EHC), Hims & Hers Health (HIMS) and Trevi Therapeutics (TRVI) - The Globe and Mail
Hims & Hers abandons copycat weight-loss drug in face of FDA probe - Financial Times
Hims & Hers Scraps Copycat Wegovy Weight-Loss Pill After Probe - bloomberg.com
Key facts: Hims & Hers Health shares drop 14.1%; FDA restricts weight-loss pill - TradingView
Hims to stop offering copy of Wegovy pill following FDA scrutiny - Sherwood News
Hims & Hers to stop offering copies of Novo Nordisk's new Wegovy pill - marketscreener.com
Hims & Hers to Stop Offering Compounded Semaglutide Pill After FDA Crackdown - US News Money
Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown - marketscreener.com
Hims & Hers Health Inc says we have decided to stop offering access to compounded semaglutide pill - marketscreener.com
Hims & Hers Health Inc Says We Have Decided To Stop Offering Access To Compounded Semaglutide Pill - TradingView
Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding’ Over Cheaper Wegovy Version - The Wall Street Journal
Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action - AOL.com
HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch - Stocktwits
Analysts Conflicted on These Healthcare Names: Cigna (CI), Hims & Hers Health (HIMS) and Omnicell (OMCL) - The Globe and Mail
Weight-loss drugs to dominate Super Bowl advertising - Reuters Connect
HIMS Stock Slumps After-Hours On FDA Crackdown, Regulatory Scrutiny Over Compounded Wegovy Pill Launch - Stocktwits
Hims & Hers Stock Pre-Market (-16%): FDA Crackdown on New Weight-Loss Pill - Trefis
Weight-loss drugs to compete on biggest stage with Super Bowl ads - Reuters
The healthcare companies advertising in Super Bowl LX - Modern Healthcare News
Hims & Hers Stock Pre-Market (-16%) : DOJ Probe & FDA Crackdown on Weight-Loss Drugs - Trefis
HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight - Law360
Health Regulators Ask DOJ to Investigate Hims & Hers. The Stock Plunges. - Barron's
US signals crackdown on compounded weight-loss drugs; Hims shares tumble - Reuters
Health Agency Refers Knockoff GLP-1 Provider Hims & Hers to Justice Department - The Wall Street Journal
US announces crackdown on copycat weight-loss drugs - Financial Times
FDA to Restrict Copycat Weight Loss Drugs Sold by Pharma Rivals (HIMS) - bloomberg.com
FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs - The Wall Street Journal
HIMSS Health Faces DOJ Investigation for Potential Legal Violati - GuruFocus
HIMS Shares Decline 13% After Market Hours - GuruFocus
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):